Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stacy Oshry

Internal Medicine Springfield, VA Medical Doctor

NPI 1225038466 CMS profile 996152

5510 Alma Ln, Springfield, VA 22151

Open in the dashboard

General payments

$6,174

339 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stacy Oshry of Springfield, VA is reported in the CMS Open Payments database as having received $6,174 across 339 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,221 64
2024 General $1,025 58
2023 General $870 49
2022 General $929 52
2021 General $1,085 61
2020 General $239 10
2019 General $804 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stacy Oshry
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Stacy Oshry were reported at $1,221. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Stacy Oshry Internal Medicine median Middle half National median
2019 $804 $159 $48–$570 $163
2020 $239 $119 $33–$402 $114
2021 $1,085 $135 $37–$521 $132
2022 $929 $141 $42–$496 $149
2023 $870 $149 $45–$519 $160
2024 $1,025 $154 $47–$537 $164
2025 $1,221 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,277 82 payments
  2. Novo Nordisk Inc $1,039 51 payments
  3. Amgen Inc. $593 33 payments
  4. Pfizer Inc. $574 35 payments
  5. Astellas Pharma US Inc $307 8 payments
  6. AstraZeneca Pharmaceuticals LP $303 18 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $206 12 payments
  8. Nestle HealthCare Nutrition Inc. $141 6 payments
  9. Lilly USA, LLC $133 8 payments
  10. Amneal Pharmaceuticals LLC $123 5 payments
  11. Other $1,479 81 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,003 336 payments
  2. Education $172 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $552 27 payments
  2. QULIPTA $483 26 payments
  3. RYBELSUS $471 24 payments
  4. UBRELVY $447 34 payments
  5. Wegovy $331 15 payments
  6. VRAYLAR $313 17 payments
  7. NURTEC ODT $277 21 payments
  8. PREVNAR 20 $267 12 payments
  9. Repatha $243 14 payments
  10. Otezla $242 13 payments
  11. Other $3,976 238 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 141 drugs

Part D claims

7,820

Median for Internal Medicine: 777

Drug cost

$930,014

Median for Internal Medicine: $73,373

Branded share of claims

22%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 106 $153,683
Jardiance Empagliflozin Brand 99 $149,744
Ozempic Semaglutide Brand 73 $135,060
Farxiga Dapagliflozin Propanediol Brand 46 $70,775
Januvia Sitagliptin Phosphate Brand 53 $66,699
Xarelto Rivaroxaban Brand 33 $38,576
Creon Lipase/Protease/Amylase Brand 14 $38,144
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 21 $35,949
Mounjaro Tirzepatide Brand 12 $25,250
Wegovy Semaglutide Brand 14 $23,641

The 10 drugs with the highest cost, of 141 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 88 billing codes

Paid by Medicare

$565,993

Of which drugs: $102,504

Medicare patients

813

Average age 76

Services billed

15,034

358 women, 455 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 41%
Ischemic heart disease 24%
Diabetes 20%
Atrial fibrillation 18%
Cancer 16%
Chronic kidney disease 13%
Osteoporosis 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 231 231 $67,039
Sarscv2 vac 30mcg trs-suc im 91320 Office 129 134 $19,889
Vaccine for influenza for injection into muscle 90653 Office 178 179 $14,183
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 20 56 $52

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $110
$110 14 —
RYBELSUS
  • Novo Nordisk Inc $79
$79 — —
Ozempic
  • Novo Nordisk Inc $79
$79 73 —
UNITHROID
  • Amneal Pharmaceuticals LLC $76
$76 — —
QULIPTA
  • AbbVie, Inc. $75
$75 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

339 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record